Peptide education
Exenatide
Exendin-4 · Byetta · Bydureon · Bydureon BCise
Exenatide is a prescription GLP-1 receptor agonist used to improve blood glucose control in type 2 diabetes. It has been made as an immediate-release injection taken twice daily and an extended-release injection taken weekly.
Exenatide has strong clinical evidence for glucose control in type 2 diabetes. Read the specific formulation's label and check availability; twice-daily and weekly products should not be treated as interchangeable.
Overview
Quick answer
Immediate-release exenatide and Bydureon BCise are different formulations. Their meal timing, dose units, kidney precautions, age indications, and thyroid-warning language differ. A prescribing label does not establish that a product is currently stocked.
What is exenatide?
A synthetic 39-amino-acid peptide that activates the GLP-1 receptor. The molecule was originally identified in a lizard species; the drug is made synthetically.
What is it prescribed for?
The immediate-release injection label covers adults with type 2 diabetes, with diet and exercise. The Bydureon BCise label also describes use in children aged 10 and older with type 2 diabetes. Neither label is a weight-management indication.
Why do the schedules differ?
Immediate-release injection is dosed in micrograms before two meals. Bydureon BCise is an extended-release suspension labeled at 2 mg once weekly, with or without meals. The amounts and devices are not a conversion guide between products.
Is the branded product available?
An FDA review records the manufacturer's plans to discontinue marketing Byetta and Bydureon BCise. FDA also lists an approved generic immediate-release injection. Approval and an existing label do not confirm present stock, so check the exact product with a pharmacy.
Is exenatide approved specifically for weight loss?
The cited US exenatide labels are for glycemic control in type 2 diabetes. Weight changes reported during diabetes trials should not be mistaken for a separate exenatide weight-management approval.
Evidence
Evidence snapshot
Twice-daily injection before meals, alongside diet and exercise.
The label describes weekly treatment for adults and children aged 10 and older with type 2 diabetes; current supply must be checked.
A blinded trial found lower HbA1c with twice-daily exenatide than placebo at 30 weeks.
Weekly extended-release exenatide met cardiovascular safety noninferiority but not the trial's superiority threshold.
The extended-release label has a boxed warning based on rodent findings; the cited immediate-release label does not have that boxed warning.
Claims
Common claims vs evidence
| Claim | Human evidence | Mechanistic evidence | Verdict |
|---|---|---|---|
| Exenatide improves glucose control in type 2 diabetes. | In a randomized trial with background metformin, mean HbA1c at 30 weeks changed by -0.78 percentage points with 10 mcg twice daily, -0.40 with 5 mcg twice daily, and +0.08 with placebo. | Exenatide activates GLP-1 receptors and promotes insulin secretion when glucose is elevated. | Supported in the studied population and in the product labels for their specified populations. |
| Exenatide has proven cardiovascular risk reduction. | In EXSCEL, a cardiovascular composite occurred in 11.4% of participants assigned weekly exenatide and 12.2% of those assigned placebo over a median 3.2 years. The trial met noninferiority for safety but did not meet its threshold for superiority. | The trial did not establish a reduction in the primary cardiovascular outcome. | |
| A weekly exenatide dose can be substituted for the twice-daily dose. | A 28-week trial compared weekly Bydureon BCise with twice-daily Byetta for glucose control; it was not a dose-conversion study. | Incorrect. The immediate-release label specifies microgram doses before meals; the extended-release label describes a 2 mg weekly suspension and instructions for transitions. Formulation and device matter, and a transition requires product-specific medical guidance. | |
| All exenatide products have identical thyroid and kidney warnings. | The extended-release label describes postmarketing reports of acute kidney injury, often in patients with digestive symptoms and dehydration. Whether Bydureon BCise causes thyroid C-cell tumors in humans is unknown. | Incorrect. Bydureon BCise has a boxed warning about thyroid C-cell tumors in rats and an MTC or MEN2 contraindication; the immediate-release label does not carry that box. Their renal precautions also use different thresholds. |
Bottom line
Main takeaway
Twice-daily and once-weekly exenatide are not simply different reminders for the same injection.
The labels contain formulation-specific kidney precautions and warn about low blood glucose with insulin or sulfonylureas.
Glycemic improvement in a diabetes trial is not the same as a demonstrated cardiovascular or weight-management indication.
Identity
What it is
Exenatide is a synthetic peptide that binds the GLP-1 receptor. Its sequence partially overlaps human GLP-1, and the molecule was initially identified in the species Heloderma suspectum.
Byetta was the immediate-release brand. Bydureon BCise used an extended-release suspension in an autoinjector. FDA has recorded manufacturer plans to discontinue marketing both brands, while listing approval of a generic immediate-release product.
Use context
Routes, doses, and cycle patterns
Immediate-release exenatide is injected twice daily before meals. Bydureon BCise is an extended-release formulation given once weekly, with or without meals. The formulations have different dose units and devices.
Human studies and product labels
Immediate-release exenatide injection label
- Purpose
- Glycemic control in adults with type 2 diabetes
- Context
- US prescribing label
- Route
- Subcutaneous injection
- Amount
- 5 mcg twice daily initially; may increase to 10 mcg twice daily after one month based on response
- Frequency
- Twice daily within 60 minutes before morning and evening meals, or two main meals at least about six hours apart
- Duration
- Ongoing treatment as directed by the prescriber
Do not administer after a meal. If a dose is missed, the label says to resume with the next scheduled dose.
Bydureon BCise extended-release label
- Purpose
- Glycemic control in adults and children aged 10 and older with type 2 diabetes
- Context
- US product label; check current availability
- Route
- Subcutaneous injection
- Amount
- 2 mg extended-release suspension
- Frequency
- Once every seven days, with or without meals
- Duration
- Ongoing treatment as directed by the prescriber
The label specifies stopping another exenatide product before starting Bydureon BCise. An FDA review records a manufacturer plan to discontinue marketing, so the label is not evidence of current stock.
Exenatide added to metformin trial
- Purpose
- Glycemic control in adults with type 2 diabetes
- Context
- Study-reported regimen
- Route
- Subcutaneous injection
- Amount
- 5 mcg twice daily for four weeks, followed by 5 or 10 mcg twice daily; placebo was the comparator
- Frequency
- Twice daily
- Duration
- 30 weeks of study treatment
All groups continued metformin during the trial.
EXSCEL cardiovascular outcomes trial
- Purpose
- Cardiovascular outcomes in adults with type 2 diabetes
- Context
- Study-reported regimen
- Route
- Subcutaneous injection
- Amount
- 2 mg extended-release exenatide or placebo
- Frequency
- Once weekly
- Duration
- Median follow-up 3.2 years
The trial established noninferiority for the primary cardiovascular safety outcome, not superiority over placebo.
What varies
- Formulation: the weekly suspension and twice-daily solution have different devices, dose units, and meal instructions.
- Kidney function: the immediate-release label and the Bydureon BCise label use different renal thresholds and measures.
- Availability: generic approval and a published label are not proof that a particular pharmacy has the product.
Research
Research evidence
Randomized trials provide evidence for glycemic control in type 2 diabetes. The 30-week metformin study tested immediate-release doses, while EXSCEL tested extended-release exenatide for cardiovascular outcomes. EXSCEL met the threshold for cardiovascular safety but did not show superiority over placebo.
| Study / evidence area | Population | Design | Product context | Main outcome | Limitations | Weight |
|---|---|---|---|---|---|---|
| Immediate-release exenatide plus metformin | 336 adults with type 2 diabetes inadequately controlled on metformin | Randomized, blinded, placebo-controlled trial | Twice-daily exenatide or placebo with background metformin | At 30 weeks, mean HbA1c change was -0.78 percentage points with 10 mcg, -0.40 with 5 mcg, and +0.08 with placebo. | The trial studied glycemic control in metformin-treated adults over 30 weeks, not a weight-management indication. | Strong |
| EXSCEL cardiovascular outcomes trial | 14,752 adults with type 2 diabetes, with or without prior cardiovascular disease | Randomized, placebo-controlled outcomes trial | Weekly extended-release exenatide or placebo | A cardiovascular composite occurred in 11.4% versus 12.2%; noninferiority for safety was met, but superiority was not. | The primary outcome and studied formulation do not establish a cardiovascular benefit for other products or populations. | Strong for the measured outcome |
Cautions
Safety and unknowns
- Gastrointestinal effects such as nausea and vomiting are common. The labels warn about pancreatitis and acute kidney injury, which can follow dehydration from digestive symptoms. Severe gastroparesis is a specific concern in both labels.
- The immediate-release label does not recommend use with creatinine clearance below 30 mL/min or end-stage renal disease. Bydureon BCise is not recommended with estimated glomerular filtration rate below 45 mL/min/1.73 m2 or end-stage renal disease. These are different measures.
- Bydureon BCise has a boxed warning based on thyroid C-cell tumors in rats; whether it causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN2. The cited immediate-release label does not contain this boxed warning.
- Insulin or sulfonylureas can increase hypoglycemia risk. The labels also warn about serious hypersensitivity, immune-mediated thrombocytopenia, gallbladder disease, and aspiration during anesthesia or deep sedation. Extended-release injection-site reactions can be serious.
Product quality
Product identity and quality
Immediate-release solution and extended-release suspension have different formulations and devices. FDA does not approve compounded drugs or review them for safety, effectiveness, and quality before marketing.
Product and formulation
The active ingredient does not identify release characteristics, labeled dose, or device.
Availability and source
A label or approval record does not establish present stock at a particular pharmacy.
Mechanism
How it is proposed to work
Exenatide activates the GLP-1 receptor. It helps the pancreas release insulin when glucose is high, affects glucagon release, and slows gastric emptying. These effects help explain its use in type 2 diabetes.
Exenatide is a synthetic 39-amino-acid peptide with partial sequence overlap with human GLP-1.
The Bydureon BCise label describes extended-release microspheres in an injectable suspension.
Details
Technical details
Sources
References
- 1.
FDA. Compounding and the FDA: Questions and Answers
FDA explains that compounded drugs are not FDA-approved and that FDA does not verify their safety, effectiveness, or quality before marketing.
- 2.
doi:10.2337/diacare.28.5.1092 PMID:15855572
Placebo-controlled study of twice-daily exenatide added to metformin.
- 3.
PubMed. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
doi:10.1056/NEJMoa1612917 PMID:28910237 NCT01144338
Placebo-controlled cardiovascular outcomes trial of once-weekly extended-release exenatide.
- 4.
DailyMed. Exenatide injection prescribing information
Immediate-release injection label for adult type 2 diabetes, meal timing, dosage, and warnings.
- 5.
DailyMed. Bydureon BCise (exenatide) extended-release prescribing information
Extended-release product label, weekly dosing, pediatric indication, kidney precautions, and boxed warning.
- 6.
FDA. Exenatide Pediatric Postmarketing Pharmacovigilance Review
FDA review records the manufacturer's plans to discontinue Byetta and Bydureon BCise marketing, not present-day stock.
- 7.
FDA. FDA first generic drug approvals
FDA lists an approved generic exenatide injection referencing Byetta; approval does not establish pharmacy stock.